We are Sorry, This Page doesn't Exist

Activist investor Starboard Value LP plans to vote against Bristol-Myers Squibb Co's proposed $74 billion takeover of biotech Celgene Corp and urged other shareholders to join it in voting down the "poorly conceived and ill-advised" deal......»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Bristol-Myers Squibb Co and Celgene Corp have won U.S. antitrust approval for their merger on condition that they sell Celgene's psoriasis drug Otezla, the Federal Trade Commission said in a statement on Friday......»»

Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter of 2018. Tren.....»»

Celgene Corp will sell its psoriasis drug Otezla for $13.4 billion in cash to Amgen Inc, taking Celgene a step closer to a $74-billion takeover by Bristol-Myers Squibb Co......»»

Billionaire Investor David Einhorn Breaks Down Why He Just Started Shorting the US Credit Market (Business Insider) David Einhorn has earned .....»»

Some of the stocks that may grab investor focus today are: Wall Street expects Bristol-Myers Squibb Company (NYSE: BMY) to rep.....»»

Buy Celgene, Sell Bristol-Myers Squibb Ahead Of Merger Closing.....»»

Bristol-Myers Squibb Co. said Monday a late-stage study of its Opdivo as a treatment for a type of liver cancer failed to meet its main goals. The company said the Phase 3 study called CheckMate -459 evaluating Opdivo versus sorafenib as a .....»»

Bristol-Myers Squibb Co's shareholders voted to approve the drugmaker's $74 billion takeover of biotech Celgene Corp on Friday despite a campaign by activist hedge fund Starboard Value LP to scuttle the deal......»»

Activist hedge fund Starboard Value LP said on Friday it will no longer urge shareholders to oppose Bristol-Myers Squibb Co's plans to buy Celgene Corp, even though it thinks the deal is too risky and will vote its own shares against it......»»

Could Starboard Value‘s “nutritional broth for cells” be to Bristol-Myers Squibb what salting the water was to Olive Garden? This week, the activist published a 197-slide presentation outlining its objections to the merger of Bristol-Myers and .....»»

Bristol-Myers Squibb Co.'s agreement to acquire Celgene Corp. is "an exit opportunity for Celgene shareholders," Leerink analysts wrote in a note to investors Thur.....»»

An analyst upgrade—and renewed interest in biotechs after Bristol-Myers Squibb announced a deal to buy Celgene—have help Gilead’s stock rise......»»

Roche and Bristol-Myers Squibb are most exposed among large-cap pharmaceuticals firms to Medicare Plan B sales, notes Credit Suisse......»»

Activist hedge fund Starboard Value LP has asked a proxy solicitor to probe the level of support among Bristol-Myers Squibb Co shareholders for the U.S. drug maker's $74 billion deal to buy Celgene Corp, people familiar with the matter said on Friday......»»

Bristol-Myers Squibb Co. said on Wednesday that activist hedge fund Starboard Value LP wants to add five directors to its board and bought one million shares after the pharmaceutical company said it plans to buy biotech company Celgene Corp......»»

Activist investor Starboard is unhappy with Bristol-Myers’ deal to buy Celgene. The drugmaker’s fifth-largest shareholder, Dodge & Cox, is also unhappy with the deal......»»

It’s not often that a company wants to advertise the fact that it is being targeted by an activist, but that is exactly what Bristol-Myers Squibb appears to have done this week. In a prospectus rel.....»»

Bristol-Myers Squibb Co expressed disappointment on Thursday with the opposition of its top shareholder to a $74 billion takeover of Celgene Corp, and said it would press on with what would be the largest pharmaceutical acquisition of all time......»»